Treatments

First Oral Smallpox Treatment Submitted to FDA for NDA

First Oral Smallpox Treatment Submitted to FDA for NDA

By

A new drug application was submitted to the FDA for oral formula to treat smallpox.

MicroRNAs in Infectious Disease: Emerging Clinical Applications

MicroRNAs in Infectious Disease: Emerging Clinical Applications

By

MicroRNAs are currently under investigation for various clinical applications in infectious disease because of their role in host response to infection and effects on innate and adaptive immune pathways.

Fecal Microbial Transplantation by Oral Capsule Not Inferior to Colonoscopy Delivery

Fecal Microbial Transplantation by Oral Capsule Not Inferior to Colonoscopy Delivery

By

A study investigated whether fecal microbiota transplantation delivered via oral capsules was as effective as microbiota delivered via colonoscopy for treating recurrent Clostridium difficile infection.

Efficacy of LDV/SOF for Retreatment of Chronic HCV in SOF-Experienced Patients

Efficacy of LDV/SOF for Retreatment of Chronic HCV in SOF-Experienced Patients

By

The highest SVR12 rates were obtained with 12 weeks of LDV/SOF+RBV in noncirrhotic participants and by extending the duration of LDV/SOF treatment to 24 weeks in cirrhotic individuals.

Fast Track Designation for Novel Monoclonal Antibody Targeting Influenza A

Fast Track Designation for Novel Monoclonal Antibody Targeting Influenza A

By

The FDA has granted Fast Track designation to Visterra's lead product, VIS410.

Trimethoprim-Sulfamethoxazole Effective Regardless of Abscess Size

Trimethoprim-Sulfamethoxazole Effective Regardless of Abscess Size

By

Trimethoprim-sulfamethoxazole appears to improve cure rates after incision and drainage of MRSA abscesses regardless of patient characteristics.

Update on Latent Tuberculosis Testing and Treatment

Update on Latent Tuberculosis Testing and Treatment

By

A representative from the California Department of Public Health discusses latent TB infection testing and treatment recommendations and reasons why US physicians have been slow to test for and treat for the condition.

FDA Approves Labeling Update for Several HCV Drugs

FDA Approves Labeling Update for Several HCV Drugs

By

Updated labeling has been provided for several treatments for hepatitis C virus infections.

Combination β-lactam, Macrolide Pneumonia Therapy in Children Not More Effective

Combination β-lactam, Macrolide Pneumonia Therapy in Children Not More Effective

By

The results of this study question the routine empirical use of macrolide combination therapy in this population.

Treatment of Neurologic Complications in Infective Endocarditis

Treatment of Neurologic Complications in Infective Endocarditis

By

Mortality rates associated with infective endocarditis range from 16% to 25%, with the highest rates observed among patients with nosocomial healthcare-associated infective endocarditis.

Likelihood of Self-Administered Treatment Completion for Latent TB

Likelihood of Self-Administered Treatment Completion for Latent TB

By

The iAdhere study found that once-weekly self-administration of isoniazid and rifapentine had high treatment completion rates in the United States, Hong Kong, Spain, and South Africa.

Tenofovir Use Safe During Pregnancy

Tenofovir Use Safe During Pregnancy

By

Further research on longer-term effects of maternal prenatal TDF use is important given the majority of HIV-infected women are prescribed a TDF-containing prevention of mother-to-child transmission regimen.

Dual Regimen Provides Simple and Safe Salvage Therapy in HIV-1

Dual Regimen Provides Simple and Safe Salvage Therapy in HIV-1

By

Switching to dolutegravir plus darunavir/ritonavir provided a simple and safe rescue regimen, controlling viral replication in a high proportion of patients.

Diclofenac Inferior to Norfloxacin for UTI Symptom Relief

Diclofenac Inferior to Norfloxacin for UTI Symptom Relief

By

NSAIDs were found to be inferior to antibiotics for symptom relief of uncomplicated urinary tract infection.

A New Treatment Option for Patients With HCV and Severe Renal Impairment

A New Treatment Option for Patients With HCV and Severe Renal Impairment

By

Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, exhibit potent antiviral activity across all six major HCV genotypes.

Intravenous Zanamivir Safe, Efficacious in Children With Influenza

Intravenous Zanamivir Safe, Efficacious in Children With Influenza

By

Zanamivir is a neuraminidase inhibitor approved in the United States as an oral inhalation powder for acute, uncomplicated influenza in children ≥7 years of age and prophylaxis in children ≥5 years of age.

Rates of Infection in Juvenile Idiopathic Arthritis Treated With Biologic Therapy

Rates of Infection in Juvenile Idiopathic Arthritis Treated With Biologic Therapy

By

Researchers examine serious infection risk factors in patients with juvenile idiopathic arthritis receiving biologic therapy.

Short-Duration Treatment Regimens for Chronic HCV: Latest Insights

Short-Duration Treatment Regimens for Chronic HCV: Latest Insights

By

The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved treatment adherence, and a reduced rate of side effects.

Efficacy of <i>Goshuyuto</i>/Rabeprazole for Refractory <i>H pylori</i>

Efficacy of Goshuyuto/Rabeprazole for Refractory H pylori

Refractory Helicobacter pylori infection can be successfully treated with goshuyuto and rabeprazole.

Fixed-Dose Meropenem-Vaborbactam Available for Complicated UTI, Pyelonephritis

Fixed-Dose Meropenem-Vaborbactam Available for Complicated UTI, Pyelonephritis

By

Vabomere is now available for the treatment of adults (≥18 years old) with complicated urinary tract infections.

HCV Eradication With DAAs Associated With Reduced HCC Risk

HCV Eradication With DAAs Associated With Reduced HCC Risk

By

Treatment of hepatitis C virus with direct-acting antivirals was tied to a 71% reduction in the risk of liver cancer.

Secnidazole Efficacious in Treatment of Bacterial Vaginosis

Secnidazole Efficacious in Treatment of Bacterial Vaginosis

By

Secnidazole is a 5-nitroimidazole with demonstrated in vitro antimicrobial activity against many anaerobic Gram-negative and Gram-positive bacterial species, while sparing Lactobacillus species.

Antibiotic Stepdown Tx for Uncomplicated Gram-Negative Bloodstream Infections

Antibiotic Stepdown Tx for Uncomplicated Gram-Negative Bloodstream Infections

By

For uncomplicated Gram-negative bloodstream infections, oral beta-lactam therapy may be an appropriate stepdown option.

Lower Risk of <i>C Difficile</i> Infection With Tetracycline Use

Lower Risk of C Difficile Infection With Tetracycline Use

By

Researchers conducted a systemic review and meta-analysis to determine which antibiotics for systemic use were associated with the lowest risk of C difficile infection.

Inappropriate Antibiotic Prescribing Rates High for Uncomplicated UTIs

Inappropriate Antibiotic Prescribing Rates High for Uncomplicated UTIs

By

Inappropriate prescribing of outpatient antibiotics for the treatment of uncomplicated urinary tract infections are higher than previously estimated.

Antibiotic Regimen Strategy for Improving Severe Community-Acquired Pneumonia

Antibiotic Regimen Strategy for Improving Severe Community-Acquired Pneumonia

By

Patients who seem to benefit most from the combination of a macrolide with a β-lactam are patients with bacteremic pneumococcal pneumonia, septic shock, and invasive mechanical ventilation.

HIV/HCV Co-Infections: Barriers to Effective Treatment

HIV/HCV Co-Infections: Barriers to Effective Treatment

By

Only a small percentage of people with HIV/HCV co-infection receive treatment for hepatitis C.

Pediatric Outpatient Antimicrobial Stewardship: Minimizing Antibiotic Duration

Pediatric Outpatient Antimicrobial Stewardship: Minimizing Antibiotic Duration

Hear from experts on when to prescribe short course antibiotic therapy in pediatric populations for a variety of common infections.

Weight-Based Dosing of Clindamycin and TMP/SMX Improves Cellulitis Outcomes

Weight-Based Dosing of Clindamycin and TMP/SMX Improves Cellulitis Outcomes

By

Weight-based dosing options for treatment may improve clinical outcomes in patients with cellulitis.

Latent Tuberculosis May Benefit From 3-Month Rifapentine, Isoniazid Tx

Latent Tuberculosis May Benefit From 3-Month Rifapentine, Isoniazid Tx

By

Three months of rifapentine + isoniazid using directly observed therapy resulted in a higher completion rate and no loss of follow-up for latent tuberculosis.

Sign Up for Free e-newsletters